[go: up one dir, main page]

MX2022001449A - Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. - Google Patents

Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.

Info

Publication number
MX2022001449A
MX2022001449A MX2022001449A MX2022001449A MX2022001449A MX 2022001449 A MX2022001449 A MX 2022001449A MX 2022001449 A MX2022001449 A MX 2022001449A MX 2022001449 A MX2022001449 A MX 2022001449A MX 2022001449 A MX2022001449 A MX 2022001449A
Authority
MX
Mexico
Prior art keywords
same
methods
ent
human
compositions including
Prior art date
Application number
MX2022001449A
Other languages
English (en)
Inventor
Michael Zasloff
Denise Barbut
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of MX2022001449A publication Critical patent/MX2022001449A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere generalmente a nuevos compuestos de aminoesterol, a composiciones que comprenden los mismos y a métodos para preparar y usar los nuevos compuestos y composiciones de aminoesterol.
MX2022001449A 2019-08-02 2020-07-31 Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. MX2022001449A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882358P 2019-08-02 2019-08-02
US202063041031P 2020-06-18 2020-06-18
PCT/US2020/044390 WO2021025973A1 (en) 2019-08-02 2020-07-31 Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same

Publications (1)

Publication Number Publication Date
MX2022001449A true MX2022001449A (es) 2022-04-06

Family

ID=74502413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001449A MX2022001449A (es) 2019-08-02 2020-07-31 Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.

Country Status (8)

Country Link
US (1) US12503485B2 (es)
EP (1) EP4007764B1 (es)
JP (1) JP2022543242A (es)
CN (1) CN114929724B (es)
AU (1) AU2020324937A1 (es)
CA (1) CA3149479A1 (es)
MX (1) MX2022001449A (es)
WO (1) WO2021025973A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021025974A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same
WO2021216399A1 (en) * 2020-04-20 2021-10-28 Enterin, Inc. Pulmonary aminosterol compositions and methods of using the same to treat microbial infections
US20250228873A1 (en) * 2022-01-25 2025-07-17 Enterin, Inc. C25 r and s isomers of aminosterols and methods of making and using the same
CN119768413A (zh) * 2022-06-29 2025-04-04 因特尔公司 氨基甾醇化合物、氨基甾醇-环糊精制剂和使用它们的方法
CN118085053A (zh) * 2022-11-25 2024-05-28 深圳先进技术研究院 以Inx5基因或以Inx5蛋白作为作用靶点的物质的应用
CN119770654A (zh) * 2025-01-08 2025-04-08 南京大学 Parp1抑制剂在制备治疗和/或缓解弗里德赖希氏共济失调的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
AU3512595A (en) 1994-09-13 1996-03-29 Magainin Pharmaceuticals, Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
CA2223910C (en) 1995-06-07 2008-09-16 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
EP3293195A1 (en) * 2007-09-06 2018-03-14 OHR Pharmaceutical, Inc. Compounds for use in treating diabetes
EP3556765B1 (en) 2012-04-20 2022-02-23 OHR Pharmaceutical, Inc. Aminosteroids for the treatment of a ptp1b associated disease
CA2896073C (en) * 2012-12-20 2021-10-19 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
GB201303589D0 (en) * 2013-02-27 2013-04-10 Univ Swansea Compound and method for the treatment of neurodegenerative conditions
GB201316050D0 (en) * 2013-09-10 2013-10-23 Univ Swansea Deuterated compounds
AU2014364850A1 (en) * 2013-12-20 2016-07-07 Prevacus, Inc. Synthesis of ent-progesterone and intermediates thereof
FR3055802B1 (fr) 2016-09-15 2018-08-24 Virbac Derives amides de squalamine pour le traitement des infections
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
EP4427738A3 (en) * 2019-08-02 2024-12-04 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment
WO2021025974A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same

Also Published As

Publication number Publication date
CN114929724B (zh) 2024-12-10
AU2020324937A1 (en) 2022-03-10
JP2022543242A (ja) 2022-10-11
US12503485B2 (en) 2025-12-23
EP4007764A1 (en) 2022-06-08
EP4007764B1 (en) 2026-01-21
US20230123701A1 (en) 2023-04-20
EP4007764A4 (en) 2023-08-09
WO2021025973A1 (en) 2021-02-11
CN114929724A (zh) 2022-08-19
CA3149479A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
CL2020002801A1 (es) Anticuerpos monoclonales contra bcma (divisional de solicitud 201800281).
CL2021003373A1 (es) Nuevos inhibidores de egfr
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
MX2020009347A (es) Picolinamidas como fungicidas.
CO2020016285A2 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
MX2021006977A (es) Anellosomas y metodos de uso.
CR20190566A (es) Inhibidores de quinasay usos de los mismos
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
UY38377A (es) Piridazinonas y sus métodos de uso
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
MX2019009759A (es) Composiciones de peptido estables.
CL2020002217A1 (es) Uso de alcoxipirazoles como inhibidores de la nitrificación
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
CR20220292A (es) Tiofenocarboxamidas sustituidas y sus derivados
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida